Exécution de notre outil de synthèse sur un nouvel article
Vérifiez l’article ci-dessous, puis lancez sa synthèse.
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
Bertrand Routy (Inserm, Université Paris-Saclay), Emmanuelle Le Chatelier (Université Paris-Saclay, MetaGenoPolis), Lisa Derosa (Inserm, Université Paris-Saclay), Connie P.M. Duong (Inserm, Institut Gustave Roussy), Maryam Tidjani Alou (Inserm, Université Paris-Saclay), Romain Daillère (Inserm, Université Paris-Saclay), Aurélie Fluckiger (Inserm, Institut Gustave Roussy), Meriem Messaoudene (Inserm, Institut Gustave Roussy), Conrad Rauber (Inserm, Université Paris-Saclay), María Paula Roberti (Inserm, Institut Gustave Roussy), Marine Fidelle (Université Paris-Saclay, Institut Gustave Roussy), Caroline Flament (Inserm, Institut Gustave Roussy), Vichnou Poirier-Colame (Inserm, Institut Gustave Roussy), Paule Opolon (Institut Gustave Roussy), Christophe Klein (Inserm, Sorbonne Université), Kristina Iribarren (Inserm, Sorbonne Paris Cité), Laura Mondragón (Inserm, Sorbonne Paris Cité), Nicolas Jacquelot (Inserm, Université Paris-Saclay), Bo Qu (Inserm, Université Paris-Saclay), Gladys Ferrere (Inserm, Université Paris-Saclay), Céline Clémenson (Inserm, Université Paris-Saclay), Laura Mezquita (Institut Gustave Roussy, Fondation Gustave Roussy), Jordi Remon Masip (Institut Gustave Roussy, Fondation Gustave Roussy), Charles Naltet (Assistance Publique – Hôpitaux de Paris, Hôpital Bichat-Claude-Bernard), Solenn Brosseau (Assistance Publique – Hôpitaux de Paris, Hôpital Bichat-Claude-Bernard), Courèche Kaderbhaï (Centre Georges François Leclerc), Corentin Richard (Centre Georges François Leclerc), Hira A. Rizvi (Memorial Sloan Kettering Cancer Center), Florence Levenez (Université Paris-Saclay, MetaGenoPolis), Nathalie Galleron (Université Paris-Saclay, MetaGenoPolis), Benoît Quinquis (Université Paris-Saclay, MetaGenoPolis), Nicolas Pons (Université Paris-Saclay, MetaGenoPolis), Bernhard Ryffel (Université d'Orléans, Centre National de la Recherche Scientifique), Véronique Minard‐Colin (Institut Gustave Roussy), Patrick Gonin (Institut Gustave Roussy), Jean‐Charles Soria (Institut Gustave Roussy, Fondation Gustave Roussy), Éric Deutsch (Inserm, Université Paris-Saclay), Yohann Loriot (Université Paris-Saclay, Institut Gustave Roussy), François Ghiringhelli (Centre Georges François Leclerc), Gérard Zalcman (Assistance Publique – Hôpitaux de Paris, Hôpital Bichat-Claude-Bernard), François Goldwasser (Sorbonne Paris Cité, Hôpital Cochin), Bernard J. Escudier (Inserm, Institut Gustave Roussy), Matthew David Hellmann (Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine), Alexander M.M. Eggermont (Inserm, Institut Gustave Roussy), Didier Raoult (Centre National de la Recherche Scientifique, Inserm), Laurence K. Albiges (Université Paris-Saclay, Institut Gustave Roussy), Guido Kroemer (Karolinska University Hospital, Inserm), Laurence Zitvogel (Inserm, Université Paris-Saclay)
Résumé : Good bacteria help fight cancer Resident gut bacteria can affect patient responses to cancer immunotherapy (see the Perspective by Jobin). Routy et al. show that antibiotic consumption is associated with poor response to immunotherapeutic PD-1 blockade. They profiled samples from patients with lung and kidney cancers and found that nonresponding patients had low levels of the bacterium Akkermansia muciniphila . Oral supplementation of the bacteria to antibiotic-treated mice restored the response to immunotherapy. Matson et al. and Gopalakrishnan et al. studied melanoma patients receiving PD-1 blockade and found a greater abundance of “good” bacteria in the guts of responding patients. Nonresponders had an imbalance in gut flora composition, which correlated with impaired immune cell activity. Thus, maintaining healthy gut flora could help patients combat cancer. Science , this issue p. 91 , p. 104 , p. 97 ; see also p. 32